Composite and pragmatic measures in psoriatic arthritis: bridging trials and clinical feasibility

A layered framework - rapid screening with DAPSA, target verification via MDA, deep evaluation using PASDAS or Short Form-36, and patient-anchored monitoring with PsAID-12 - allows multidimensional assessment within minutes. Future directions emphasize outcome personalization, integrating biomarkers, imaging, and PROs into adaptive algorithms that support shared decision-making. Ultimately, outcome measures should evolve from static scores into dynamic tools that guide both clinical trials and everyday PsA care.